Abstract
We used the latency of the P1 cortical auditory-evoked potential (CAEP) as a biomarker for the development of central auditory pathways in three children who received intervention through hearing aids and/or cochlear implants. Our goal was to examine the clinical feasibility of using the latency of the P1 CAEP as an objective tool to evaluate whether acoustic amplification for hearing-impaired children has provided sufficient stimulation for normal development of central auditory pathways. If clinicians have such a marker, then they can more confidently make a decision about whether to provide a child with a cochlear implant following an appropriate hearing-aid trial. Using the same marker, clinicians will also be able to monitor the maturation of central auditory pathways once electrical stimulation is initiated.
Original language | English (US) |
---|---|
Pages (from-to) | 564-573 |
Number of pages | 10 |
Journal | Journal of the American Academy of Audiology |
Volume | 16 |
Issue number | 8 |
DOIs | |
State | Published - 2005 |
Keywords
- Amplification
- Biomarker
- Cochlear implant
- Cortical auditory evoked potential
- Hearing aid
- Hearing impairment
- Objective measure
- P1
- Plasticity
ASJC Scopus subject areas
- Speech and Hearing